Somatotropin
- Generic Name
- Somatotropin
- Brand Names
- Genotropin, Humatrope, Norditropin, Norditropin Nordiflex, Nutropin, Nutropinaq, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive, NutropinAq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 12629-01-5
- Unique Ingredient Identifier
- NQX9KB6PCL
- Background
Human growth hormone (HGH), also known as somatotropin, is a peptide hormone that is synthesized and secreted by the somatotropic cells of the anterior pituitary gland. Growth hormone plays an essential role in growth regulation during childhood as well as other basal metabolic functions, muscle and fat mass regulation, blood glucose level regulation, and li...
- Indication
Somatotropin is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, short stature associated with Turner syndrome, Prader-Willi syndrome (PWS), idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and shor...
- Associated Conditions
- Adult Onset Growth Hormone Deficiency, Cachexia, Childhood-onset Growth Hormone Deficiency, Growth Failure, HIV Wasting Syndrome, Short Bowel Syndrome (SBS), Short Stature
- Associated Therapies
- -
Somatropin Treatment to Final Height in Turner Syndrome
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 154
- Registration Number
- NCT00191113
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherbrooke, Quebec, Canada
Effect of Growth Hormone on Leptin, Cytokines and Body Composition of Children With Growth Failure Due to Chronic Kidney Disease
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-03-25
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 15
- Registration Number
- NCT00194961
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT00191360
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 112
- Registration Number
- NCT00184743
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Growth Hormone Treatment of Young Growth Hormone-Deficient Adults
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 30
- Registration Number
- NCT00187993
- Locations
- 🇫🇷
UH of Angers, Angers, France
🇫🇷UH of Brest, Brest, France
🇫🇷UH of Caen, Caen, France
Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 98
- Registration Number
- NCT00184717
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 78
- Registration Number
- NCT00184691
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 161
- Registration Number
- NCT00184678
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00182091
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy on Height in SGA Children Treated With Growth Hormone
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 151
- Registration Number
- NCT00184756
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Örebro, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.